Beta Finch - S&P 100 - EN

**BETA FINCH PODCAST SCRIPT**

---

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we turn complex financial reports into clear conversations. I'm Alex.

**JORDAN:** And I'm Jordan. Today we're diving into Blackstone's Q4 2025 earnings – and wow, what a quarter this was for the private equity giant.

**ALEX:** Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Absolutely. Now Alex, let's talk about these numbers because Blackstone just delivered what they're calling their best results in their 40-year history.

**ALEX:** The headline number that caught my eye – distributable earnings of $1.75 per share for the quarter, capping off a record year where DE increased 20% to $5.57 per share. That's $7.1 billion in distributable earnings for the full year. But Jordan, what really stood out to you?

**JORDAN:** The sheer scale of capital flows. They pulled in $71 billion in inflows just in Q4 – that's the highest level in three and a half years. For the full year, we're talking about $240 billion in fundraising. To put that in perspective, their assets under management hit nearly $1.3 trillion, up 13% year over year.

**ALEX:** That's an almost incomprehensible amount of money. And CEO Jonathan Gray made an interesting point about their market position – according to analyst research, Blackstone has an estimated 50% share of all private wealth revenue across major alternative firms.

**JORDAN:** Which brings us to one of their biggest success stories – the private wealth channel. Their fundraising there jumped 53% year over year to $43 billion. But what's driving this?

**ALEX:** Performance, performance, performance. Their BCRED product – that's their private credit offering for individual investors – delivered 10% net returns annually since inception five years ago. Their private equity flagship BXP has generated 17% annualized returns since launching just two years ago.

**JORDAN:** Let's talk about the elephant in the room though – real estate. This has been a challenging sector, but there are some interesting developments. While real estate values only appreciated about 1.5% for the full year, they're seeing positive signs.

**ALEX:** Right, construction starts have fallen to their lowest level in over 12 years in both logistics and multifamily – their two largest real estate sectors. Less supply typically means better pricing power down the road.

**JORDAN:** And they're not just sitting on the sidelines. They've deployed over $50 billion in real estate since what they call the "cycle trough" two years ago, including a Q4 commitment to privatize Alexander and Baldwin.

**ALEX:** Now let's talk about what might be the most exciting part of this call – the deal environment is finally opening up. Jonathan Gray compared it to 2013-2014, saying it feels like markets are coming out of hibernation.

**JORDAN:** The Medline IPO was a perfect example. This was a $7.2 billion IPO – the largest since 2021 and the largest sponsor-backed IPO in history. Shares popped over 40% on the first day. Gray mentioned they have "one of the largest IPO pipelines in our history."

**ALEX:** What did you make of their commentary on artificial intelligence? They seem to be positioning this as a generational investment opportunity.

**JORDAN:** It's fascinating how they're approaching it on multiple levels. They're investing in the infrastructure – data centers, power generation, the electric grid. But they're also implementing AI across their 270+ portfolio companies. CFO Michael Chae mentioned seeing real productivity gains in software engineering and cyber monitoring already.

**ALEX:** Speaking of their portfolio, the performance numbers across segments were pretty impre

This episode includes AI-generated content.

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we decode quarterly reports so you don't have to. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're diving into Bristol Myers Squibb's Q4 2025 earnings call - and let me tell you, this one was packed with updates.

But first, Jordan, I need to get our mandatory disclaimer out of the way. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN**: Thanks Alex. And speaking of packed earnings calls, Bristol Myers definitely delivered on that front. Let's start with the headline numbers because they tell quite a story about this company's transformation.

**ALEX**: Absolutely. So Q4 revenue came in flat year-over-year at about $12.5 billion, but here's the key detail that investors need to understand - their growth portfolio, which includes all their newer drugs, grew 15% in the quarter and represented nearly 60% of total revenue. That's a massive shift from where this company was just a few years ago.

**JORDAN**: Right, and for the full year, that growth portfolio grew 17%. What's really impressive is that despite losing roughly $4 billion in revenue from legacy products - we're talking about patent cliffs and generic competition - the growth portfolio almost completely offset those declines. That's the kind of pipeline execution that pharma investors dream about.

**ALEX**: Let's talk about some of those growth drivers. Reblozyl, their blood disorder treatment, crossed $2 billion in annual sales. Breyanzi, their CAR-T cell therapy, grew 47% in Q4. And then you have Camzyos for heart disease growing 57%. These aren't just incremental gains - these are blockbuster-level products hitting their stride.

**JORDAN**: And here's what caught my attention from CEO Christopher Boerner's comments - he emphasized they're entering 2026 with "good momentum." But the real story is what's coming in the pipeline. They're expecting six registrational data readouts in the second half of 2026. That's potentially six new revenue streams or major label expansions.

**ALEX**: Jordan, let's break down that pipeline because it spans multiple therapeutic areas. You've got Milvexian for atrial fibrillation and stroke prevention - that's a massive market where they're trying to compete with their own Eliquis. Then there's admilparent for lung fibrosis, and several multiple myeloma treatments. This isn't just one bet - it's a diversified portfolio of shots on goal.

**JORDAN**: Speaking of Eliquis, that was probably the most complex part of the call. The drug is actually expected to grow 10-15% in 2026, which surprised me given it's facing patent cliffs. But management explained they took a strategic pricing reduction that eliminates certain penalty rebates while expanding patient access.

**ALEX**: That's a fascinating strategy. CFO David Elkins explained that the roughly 40% price reduction actually helps them competitively because it removes inflationary penalties that had been building up over years. It's counterintuitive - lower prices leading to higher growth - but it makes sense when you understand the complex rebate structures in pharma.

**JORDAN**: However, they're also guiding for a $1.5 to $2 billion step-down in Eliquis revenue from 2026 to 2027, primarily due to European patent expiries. So investors are looking at one good year before facing those headwinds.

**ALEX**: Let's talk about their cost management because this is where Bristol Myers is really showing discipline. They delivered $1 billion in cost savings in 2025 and expect another billion over 2026-2027. But here's the smart part - they're reinvesting some of those savings into growth initiatives like their partnership with BioNTech on pemiglatinib.

**JORDAN**: That partnership caught

This episode includes AI-generated content.

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.

JORDAN: And I'm Jordan. Today we're diving into Bank of America's Q4 2025 results, which came out this morning with some pretty solid numbers.

ALEX: Before we get started, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Absolutely. Now, let's talk about these results. Bank of America delivered $7.6 billion in net income for Q4, which is up 12% year-over-year. Earnings per share came in at 98 cents, up a whopping 18% from last year.

ALEX: That's a strong finish to 2025. What really caught my attention was the revenue growth - 7% year-over-year, led by net interest income jumping 10% to $15.9 billion. And get this - they delivered 330 basis points of operating leverage in the quarter.

JORDAN: Operating leverage is really the name of the game for banks right now, and Bank of America seems to be executing well on that front. CEO Brian Moynihan highlighted that they kept headcount flat across the entire year despite growing client activity and volumes. That's impressive discipline.

ALEX: Let's break down some of the key drivers. Loan growth was robust at 8% year-over-year, and deposits grew 3%. Both of those outpaced industry averages. What's interesting is they're seeing growth across all their business segments.

JORDAN: Right, and looking at the deposit story - this has been a challenge across the industry post-pandemic. But Bank of America actually added 680,000 new consumer checking accounts during the year while maintaining an average balance of over $9,000. That's 28 consecutive quarters of net growth, or seven straight years.

ALEX: That's remarkable consistency. Now, let's talk about their outlook because this is where it gets really interesting. CFO Alastair Borthwick reiterated their guidance for 5% to 7% net interest income growth in 2026.

JORDAN: And here's why that's significant - they have about $12 to $15 billion in mortgage-backed securities and mortgage loans rolling off each quarter in 2026. These will be replaced with new assets yielding 150 to 200 basis points higher. That's essentially free money dropping to the bottom line.

ALEX: The asset repricing story is huge for Bank of America. They've been positioned for rising rates, but even in a declining rate environment, they're benefiting from this roll-off dynamic. Speaking of rates, how are they thinking about sensitivity?

JORDAN: Good question. They said that if rates dropped another 100 basis points instantly, NII would decline by about $2 billion over 12 months. But if rates went up 100 basis points, they'd benefit by around $700 million. So they're still somewhat asset-sensitive, but much less than before.

ALEX: Let's talk about their business segments. Consumer Banking continues to be a profit machine with a 28% return on allocated capital and what looks like around a 50% profit margin.

JORDAN: And Wealth Management is really hitting its stride. Net income grew from $1 billion in Q2 to $1.4 billion in Q4, with the return on allocated capital jumping from 20% to 28%. They added $500 billion in client balances across the year to reach $4.8 trillion total.

ALEX: Global Markets had another strong quarter too - their 15th consecutive quarter of improvement in sales and trading, generating nearly $21 billion in revenue for the full year. That's a record.

JORDAN: What I found fascinating in the Q&A was the discussion around technology and AI investments. Moynihan mentioned they have 18,000 people coding at the company, and AI has already taken 30% out of the coding process, saving them about 2,000 people equivalent in productivity.

ALEX: That's the kind of operational efficiency that drives long-term competitive advantages. They're spending s

This episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**

---

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and I'm here with my co-host Jordan to dive into AMD's blockbuster Q4 2025 earnings call. Before we get started, I want to remind everyone that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex. And wow, what a quarter for AMD! Let me start with the headline numbers because they're pretty impressive. Q4 revenue hit $10.3 billion, up 34% year-over-year, and for the full year they reached a record $34.6 billion in revenue. Net income jumped 42% to $2.5 billion in the quarter.

**ALEX:** Those are strong numbers across the board. But what really caught my attention was their data center segment performance. Jordan, can you break down what's happening there?

**JORDAN:** Absolutely. The data center segment was the star of the show with $5.4 billion in revenue, up 39% year-over-year. What's fascinating is they're seeing growth on two fronts - their traditional EPYC server CPUs are crushing it, and their AI GPU business with the Instinct chips is really starting to ramp up.

**ALEX:** And Lisa Su, AMD's CEO, seemed particularly bullish about their AI prospects. She mentioned they're targeting tens of billions in AI revenue by 2027. That's a pretty bold claim.

**JORDAN:** It is bold, but they've got some big partnerships backing it up. The most notable is their multi-generation deal with OpenAI to deploy six gigawatts of Instinct GPUs. That's massive scale we're talking about. And they're expecting their next-gen MI450 chips and Helios platform to start shipping in the second half of 2026.

**ALEX:** Let's talk about that China situation though, because that added some complexity to the numbers. They had $390 million in revenue from MI308 sales to China in Q4, which wasn't in their original guidance.

**JORDAN:** Right, and that's important context. Those were from licenses approved earlier in 2025, and they're only forecasting another $100 million from China in Q1. Beyond that, they're not providing any guidance on China revenue because of the regulatory uncertainty. So investors should view those China numbers as essentially one-time benefits rather than recurring revenue.

**ALEX:** The other segment that really impressed me was their client and gaming business. $3.9 billion in revenue, up 37% year-over-year. Their Ryzen processors seem to be gaining serious market share.

**JORDAN:** That's a great point, Alex. What I found interesting is they're not just competing on the consumer side - they're making real inroads in commercial PCs. Their Ryzen CPU sell-through for commercial notebooks and desktops grew over 40% year-over-year. That's typically a stickier, higher-margin market.

**ALEX:** Speaking of margins, let's talk about profitability. Their gross margin hit 57% in Q4, though that included a one-time inventory reserve release. Even adjusting for that, they were at about 55%, which is still solid.

**JORDAN:** And Jean Hu, their CFO, seemed confident about margin progression going forward. She mentioned they're benefiting from favorable product mix across all their businesses - newer generation products in data center, moving up-market in client, and recovery in their embedded business.

**ALEX:** The Q&A session had some interesting moments too. One analyst asked about supply constraints for their server CPUs, and Lisa Su acknowledged they've been increasing supply capacity because demand has been so strong.

**JORDAN:** That's a good problem to have, but it does raise questions about whether they can meet all the demand they're seeing. Su mentioned they're working with supply chain partners on multi-year agreements, which suggests they're taking this seriously.

**ALEX:** There was a

This episode includes AI-generated content.

**Beta Finch Podcast Script: Abbott Laboratories Q4 2025 Earnings**

---

**ALEX:** Welcome back to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that move markets. I'm Alex, and as always, I'm joined by my co-host Jordan. Today we're unpacking Abbott's fourth quarter 2025 results, and folks, there's quite a story here.

Before we jump in, I need to share our standard disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

Now Jordan, Abbott just reported their Q4 numbers, and CEO Robert Ford had some interesting things to say about the year ahead. What caught your attention first?

**JORDAN:** Alex, the headline numbers tell a tale of two companies, honestly. On one hand, you've got Abbott delivering on their original double-digit EPS growth target with adjusted earnings per share hitting $1.50 – that's 12% growth year-over-year. But then there's this nutrition business headwind that's creating some near-term challenges.

**ALEX:** Right, and let's talk about that guidance because it's pretty telling. For 2026, Abbott is projecting organic sales growth of 6.5% to 7.5% – so 7% at the midpoint – and they're calling for 10% growth in adjusted EPS. That EPS growth is solid, but that revenue guidance seems a bit more cautious than what some were expecting.

**JORDAN:** Exactly, and Ford was pretty transparent about why. The nutrition business is essentially going through what he called a "transition back to a more sustainable volume-driven business." Here's what's fascinating – Abbott has been raising prices to offset post-pandemic commodity cost increases, but now those higher prices are actually suppressing demand as consumers become more price-sensitive.

**ALEX:** It's like a classic consumer goods dilemma, right? You raise prices to maintain margins, but eventually you price yourself out of volume growth. Ford mentioned they started implementing "price and promotion initiatives" in Q4 to try to reignite volume growth. How big of an impact is this having on the overall company?

**JORDAN:** Well, nutrition is a meaningful piece of Abbott's portfolio, but what I found encouraging is how Ford framed the rest of the business. He said a "significant majority of the company" is either maintaining high single-digit growth or actually accelerating. The medical devices segment, for example, grew 10.5% in the quarter.

**ALEX:** And that medical devices growth is really impressive when you dig into the details. Continuous glucose monitors grew 17% for the full year, exceeding $7.5 billion in sales. That's the third consecutive year their CGM business has grown by more than a billion dollars. Jordan, when an analyst asked about CGM growth expectations, Ford had a pretty confident response.

**JORDAN:** He did! Ford pushed back on the narrative that the CGM market is slowing down, saying "I don't consider growing a billion dollars every single year and doing it four years in a row to be slowing down." He sees continued penetration opportunities across all patient groups – intensive insulin users, basal insulin users, and non-insulin users. Plus, there's potential for expanded reimbursement coverage for non-insulin Type 2 diabetes patients.

**ALEX:** Speaking of new products, Abbott got FDA approval for their BOLT PFA catheter in December and CE Mark approval for their Tactiflex Duo ablation catheter. Ford seemed pretty excited about their electrophysiology portfolio positioning.

**JORDAN:** Absolutely. He made this great point about how three years ago, there were concerns that Abbott's EP franchise would struggle without PFA technology, but they've maintained double-digit growth even without those products. Now with Volt launching in the US and Tactiflex Duo internationally, Ford said "I do

This episode includes AI-generated content.

**Beta Finch Podcast Script: Johnson & Johnson Q4 2025**

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that matter. I'm Alex, and joining me as always is my co-host Jordan. Today we're dissecting Johnson & Johnson's Q4 2025 earnings call, and wow - what a way to cap off the year.

Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Thanks Alex, and yeah, JNJ really delivered here. They're calling 2025 a "catapult year" - and the numbers back that up. Let's start with the headline figures because they're impressive across the board.

ALEX: Absolutely. Fourth quarter operational sales growth came in at 7.1%, which is solid, but the full-year picture is even better. They hit $94.2 billion in total revenue for 2025 with 5.3% operational growth. But here's the kicker, Jordan - they're guiding for $100 billion at the midpoint for 2026. That's a massive psychological milestone for any healthcare company.

JORDAN: Right, and what's fascinating is how they're positioning this growth. CEO Joaquin Duato kept emphasizing their "28 billion-dollar products" - that's an incredible diversification of revenue streams. No other healthcare company has that kind of breadth. They're not relying on one or two blockbusters like some of their competitors.

ALEX: Let's break down the two main segments. On the Innovative Medicine side, they posted 5.3% operational growth for the year, crossing $60 billion in pharma sales for the first time. The star performer here continues to be DARZALEX in multiple myeloma - $14 billion in annual sales with 22% growth. That's just staggering for a drug of that size.

JORDAN: And they're not stopping there. The multiple myeloma franchise is becoming a juggernaut. They mentioned being the number one company in that space, with 80% of patients treated with at least one of their four medicines. Plus, CARVICTI, their CAR-T therapy, is showing strong momentum with over 10,000 patients treated across 14 markets.

ALEX: The immunology story is equally compelling. Tremfya hit $5 billion in sales and grew 65% in Q4 - that's not a typo, sixty-five percent! They're confident it'll exceed $10 billion in peak sales, especially as it continues taking share in inflammatory bowel disease where STELARA used to dominate.

JORDAN: Speaking of STELARA, that's the elephant in the room that's actually becoming less relevant. STELARA declined 48.6% due to biosimilar competition, but here's what's remarkable - JNJ grew double digits for the full year excluding STELARA. They've successfully navigated that cliff, which was a major investor concern.

ALEX: Now let's talk MedTech. 5.4% operational growth for the year with some really strong pockets. Cardiovascular was the standout with 15% operational growth, reaching $9 billion. The Abiomed and Shockwave acquisitions are clearly paying dividends here.

JORDAN: What caught my attention was their robotics ambition. They just submitted their Ottava robotic surgery system for FDA approval via a de novo pathway - meaning there's no predicate device to compare it against. That suggests they truly believe they have something differentiated in a space dominated by Intuitive Surgical.

ALEX: The guidance for 2026 is aggressive but achievable based on their pipeline momentum. 5.7% to 6.7% operational sales growth, with that $100 billion midpoint I mentioned. Adjusted EPS growth of 5.5% at the midpoint, which factors in about $500 million in medtech tariffs - significantly higher than 2025.

JORDAN: I want to highlight something CFO Joe Wolk said about margins. They're expecting at least 50 basis points of adjusted operating margin improvement despite those tariff headwinds and increased investment in

This episode includes AI-generated content.

# Beta Finch Podcast Script: Intuitive Surgical Q4 2025 Earnings

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that move markets. I'm Alex, and joining me as always is Jordan. Today we're unpacking Intuitive Surgical's Q4 2025 results - and folks, this robotics giant just delivered some seriously impressive numbers.

Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex. And wow, where do we even start with these results? Intuitive absolutely crushed it this quarter. We're talking about a company that just crossed the 20 million patient milestone since 1997 and shows no signs of slowing down.

**ALEX:** Let's hit the headline numbers first. Revenue grew 21% to hit $10.1 billion for the full year - that's massive growth for a company this size. And quarterly revenue was up 19% to $2.87 billion. But Jordan, what really caught my eye was the procedure growth.

**JORDAN:** Absolutely. Total procedures grew 19% for the year to over 3.1 million. That's not just impressive - it's accelerating adoption of robotic surgery worldwide. Da Vinci procedures specifically were up 18%, with their single-port procedures exploding 87% year-over-year. That tells me surgeons are really embracing these newer technologies.

**ALEX:** And geographically, the story gets even better. US procedures grew 15%, but international was the real star - up 23% with particularly strong performance in Europe at 21%, Asia at 24%, and rest of world markets at 27%. It's becoming a truly global story.

**JORDAN:** What I found fascinating was the capital equipment side. They placed 1,721 da Vinci systems in 2025, including 870 of their newest da Vinci 5 systems. The demand for upgrades is clearly there, especially with the dual console systems for training and mentoring. That speaks to hospitals really investing in their robotic surgery capabilities long-term.

**ALEX:** Let's talk margins for a second. Operating margins came in at 37%, which is solid, though they're dealing with some headwinds. CEO David Rosa mentioned tariffs are hitting them for about 95 basis points, plus they're investing heavily in R&D and scaling manufacturing. But they're managing it well with cost efficiency initiatives.

**JORDAN:** The tariff impact is significant - they're forecasting 120 basis points of impact in 2026, up from about 65 basis points in 2025. That's a real cost pressure they're navigating. But here's what's interesting - they're still guiding for gross margins of 67-68% in 2026, essentially flat despite these headwinds.

**ALEX:** Now, one of the most exciting developments from this call was the FDA clearance for cardiac procedures on the da Vinci 5. Jordan, this could be huge, right?

**JORDAN:** Potentially massive, Alex. They performed about 17,000 cardiac procedures globally in 2025, which sounds small, but Rosa mentioned the addressable market for da Vinci 5 in just the US and Korea is around 160,000 procedures annually. Cardiac surgery is complex, high-value work, so even modest penetration could move the needle significantly.

**ALEX:** The Q&A session revealed some really interesting strategic directions. They're making a big push into ambulatory surgery centers - ASCs. Rosa explained they're targeting higher-volume ASCs, particularly those affiliated with existing hospital customers where surgeons are already da Vinci trained.

**JORDAN:** That ASC strategy is smart. About 70% of the ASC opportunity is with their existing IDN customers, so they have built-in relationships and trained surgeons. They're using their refurbished XI systems - the "XIR" - as the entry point, which gives them a lower-cost option for price-sensitive ASC market.

**ALE

This episode includes AI-generated content.

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that matter. I'm Alex.

**JORDAN**: And I'm Jordan. Today we're unpacking Intel's Q4 2025 earnings call, and wow - there's a lot to discuss here.

**ALEX**: Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN**: Absolutely. Now Alex, Intel's been on quite a journey lately, especially with new CEO Lip-Bu Tan at the helm. What were the headline numbers?

**ALEX**: The numbers actually look pretty solid on the surface. Q4 revenue came in at $13.7 billion - that's at the high end of their guidance range. They delivered non-GAAP earnings per share of 15 cents versus guidance of just 8 cents. And here's something interesting - this marks their fifth consecutive quarter of beating guidance.

**JORDAN**: That's a nice streak, but I'm sensing there's a "but" coming here, right?

**ALEX**: You know me too well, Jordan. The big story here isn't what they delivered - it's what they couldn't deliver due to supply constraints. CEO Lip-Bu Tan was pretty candid about this. He said they're "disappointed that we are not able to fully meet the demand in our markets."

**JORDAN**: Supply constraints in a chip shortage - where have we heard that before? But what's driving the demand they can't meet?

**ALEX**: It's all about AI infrastructure build-out. Their traditional server business saw 15% sequential growth - the fastest this decade, according to CFO Dave Zinsner. AI PCs were up 16% in units. But here's the kicker - Zinsner said revenue "would have been meaningfully higher if we had more supply."

**JORDAN**: So they're essentially leaving money on the table. What about their guidance for Q1 2026?

**ALEX**: This is where it gets interesting. They're guiding to $11.7 to $12.7 billion for Q1, with a midpoint of $12.2 billion. That's actually below typical seasonality. Zinsner said they'd be "well above seasonal if we had all the supply."

**JORDAN**: That's a pretty significant admission. But I noticed something in the transcript - they're prioritizing server shipments over client. Can you explain that strategy?

**ALEX**: Exactly right. They're deliberately shifting their constrained wafer supply toward higher-margin data center customers and away from PC clients. It's a smart move financially, but it shows just how tight their supply situation really is. They've basically depleted their inventory buffers and are operating hand-to-mouth.

**JORDAN**: Let's talk about their foundry ambitions. Lip-Bu has been making a lot of noise about building a world-class foundry business. What's the latest there?

**ALEX**: This is probably the most forward-looking part of the call. They're shipping products on Intel 18A - which they claim is the most advanced process manufactured on U.S. soil. But the real excitement is around Intel 14A. They expect customers to start making firm supplier decisions in the second half of 2026, with volume production targeted for 2028.

**JORDAN**: That timeline puts them roughly in line with TSMC's advanced nodes. But there was some interesting commentary about advanced packaging too, wasn't there?

**ALEX**: Yes! Zinsner said their advanced packaging opportunities - particularly something called EMIB-T - could be "well north of $1 billion" per customer engagement. He initially thought these would be "hundreds of millions" but customer interest is way stronger than expected. Some customers are even making prepayments to secure capacity.

**JORDAN**: That's a strong vote of confidence. Now, one thing that caught my attention was their ASIC business hitting a $1 billion run rate. That seems to be flying under the radar.

**ALEX**: Great point. Their custom ASIC business g

This episode includes AI-generated content.

# Beta Finch Podcast Script: Goldman Sachs Q4 2025 Earnings

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that move markets. I'm Alex, and joining me as always is my co-host Jordan. Today we're unpacking Goldman Sachs' fourth quarter 2025 results, and wow, what a quarter this was.

Before we jump in, I need to share our standard disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

Jordan, Goldman absolutely crushed it this quarter - $14.01 earnings per share, 16% ROE. Walk us through these headline numbers.

**JORDAN**: Alex, these results are genuinely impressive. For the full year, they delivered $51.32 in earnings per share - that's a 27% increase year-over-year. Their return on equity hit 15% for the full year and 16% return on tangible equity. But here's what really caught my attention - since their 2020 investor day, they've increased firm-wide revenues by roughly 60% and grown EPS by 144%. That's execution at scale.

**ALEX**: And they're clearly feeling confident about their position. CEO David Solomon was pretty bullish on the call, talking about how they've maintained their number one M&A adviser position for 23 consecutive years. That's remarkable staying power. But Jordan, there was some significant news buried in these results - what's the story with Apple Card?

**JORDAN**: Right, so Goldman announced they're transitioning the Apple Card portfolio. This had a net positive impact of $0.46 to EPS this quarter because while they took a $2.3 billion revenue reduction, they released $2.5 billion in reserves. Solomon called this one of their "final steps to narrow strategic focus." They're clearly trying to get out of the consumer lending business and refocus on their core strengths.

**ALEX**: Speaking of strategic focus, they laid out some pretty ambitious targets for their asset and wealth management business. What stood out to you there?

**JORDAN**: This was huge, Alex. They're increasing their pretax margin target for asset and wealth management to 30%, which they say will drive high-teen returns in that segment. They now have $3.6 trillion in assets under supervision, and they're targeting 5% long-term fee-based net inflows annually in wealth management. Solomon emphasized they see this as a massive growth opportunity - their current market share in ultra-high-net-worth is only mid-single digits despite being the leader.

**ALEX**: The investment banking outlook seems particularly interesting. They mentioned their backlog is at a four-year high. What's driving that optimism?

**JORDAN**: Solomon was really bullish here. He talked about several catalysts - corporate focus on scale and innovation, massive capital flows into AI, and increased sponsor activity. Get this - sponsors are sitting on about $1 trillion of dry powder and have roughly $4 trillion of value across their portfolio companies. Goldman's betting big that 2026 will see significant M&A activity. Solomon even suggested that in a base case scenario for M&A volumes, we could approach 2021 levels.

**ALEX**: Now, one thing that came up repeatedly was this "One Goldman Sachs 3.0" initiative powered by AI. This sounds pretty transformative, but Solomon was notably cautious about providing specific metrics. What's your read on this?

**JORDAN**: Yeah, that was interesting. Solomon emphasized this isn't about transforming the whole firm - it's about driving productivity and efficiency. They've identified six specific processes to attack with AI-driven redesign. He was pretty honest that he hoped to provide more transparency on this call but wasn't ready yet. The goal is to free up capacity to invest in growth areas like wealth management. It's a smart approach - use AI to become more eff

This episode includes AI-generated content.

# Beta Finch Podcast Script - Applied Materials Q1 2026 Earnings

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we turn complex financial reports into conversations you can actually follow. I'm Alex.

**JORDAN:** And I'm Jordan. Today we're diving into Applied Materials' Q1 2026 earnings call - that's AMAT for those keeping score at home.

**ALEX:** Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex. So Applied Materials - for folks who might not know - they're basically the behind-the-scenes heroes making the tools that manufacture semiconductors. Think of them as the company that makes the machines that make the chips.

**ALEX:** Exactly. And what's interesting about this quarter is we're seeing some really strong AI-driven demand flowing through to their business. CEO Gary Dickerson opened by highlighting "strong demand across AI, foundry-logic, and memory" with customers accelerating their technology roadmaps.

**JORDAN:** Right, and that's showing up in their financials. While they didn't give us specific revenue numbers in this transcript, CFO Brice Hill mentioned they delivered "strong revenue, margins, and cash flow" and that their backlog remains elevated with book-to-bill around unity.

**ALEX:** That book-to-bill metric is key for equipment companies like Applied Materials. When it's at or above 1.0, it means they're booking new orders at the same rate or faster than they're shipping products. It's a good leading indicator of future revenue.

**JORDAN:** What really caught my attention was the breadth of growth drivers they're seeing. It's not just one area - they mentioned AI, advanced packaging, HBM memory, and even improvements in both DRAM and NAND flash memory.

**ALEX:** HBM is High Bandwidth Memory, by the way - it's the super-fast memory that AI chips need to process all that data. Gary Dickerson specifically called out "strong pull for tools supporting HBM" with visibility extending through multiple quarters.

**JORDAN:** And here's something I found fascinating - they're not just riding the AI wave passively. When asked about advanced packaging, Dickerson talked about their "comprehensive toolset across wafer-level packaging, hybrid bonding, and inspection/metrology." They're positioning themselves across the entire value chain.

**ALEX:** That's Applied Materials' sweet spot - materials engineering. They keep emphasizing these complex new chip architectures like gate-all-around transistors and backside power delivery, which create "new materials and integration challenges" where their expertise becomes even more valuable.

**JORDAN:** Speaking of challenges, there was an interesting exchange about China and export controls. Dickerson said demand there "remains mixed by segment, with mature nodes steady and certain leading-edge areas impacted by restrictions." But they seem to be managing this well with their global footprint.

**ALEX:** Right, and what I appreciated was their transparency about supply chain issues. Brice Hill mentioned they're "expanding capacity in critical product lines" and that lead times are improving as they qualify additional suppliers. That's exactly what you want to hear from a company in this space.

**JORDAN:** The services business also looks solid. Hill talked about growth being "supported by our expanding installed base" and higher attachment to performance-based agreements. That's recurring revenue, which investors love because it's more predictable than equipment sales.

**ALEX:** Let's talk about what this means looking forward. One analyst asked about sustainability of AI demand, and Dickerson seemed pretty confident, saying their "pipeline and customer engagements give us conf

This episode includes AI-generated content.